Intarcia's Once-Yearly Diabetes Drug Bests Januvia

Will positive Phase III results for ITCA 650 versus Merck & Co.'s Januvia (sitagliptin) allow Intarcia Therapeutics to convince payers that its once- or twice-yearly diabetes medicine should be a first choice therapy for patients who fail to control their glucose with metformin?

Will positive Phase III results for ITCA 650 versus Merck & Co.'s Januvia (sitagliptin) allow Intarcia Therapeutics to convince payers that its once- or twice-yearly diabetes medicine should be a first choice therapy for patients who fail to control their glucose with metformin?

ITCA 650 nearly doubled the glucose reduction and tripled the weight loss experienced by patients with type 2 diabetes compared...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category